Novartis AG / Advanced Accelerator Applications S.A.
2017 · Acquisition/Merger · $3.9B · Complete
Announcement Sentiment
100
Strongly positive
Novartis announced a memorandum of understanding to acquire AAA via tender offer at $41/ordinary share ($82/ADS), valuing AAA equity at approximately $3.9B. The deal added Lutathera, a first-in-class lutetium-based peptide receptor radionuclide therapy for neuroendocrine tumors, plus AAA's molecular nuclear medicine manufacturing platform. The transaction was the entry point for Novartis's radioligand therapy franchise. Closed January 2018.